Reduced inflammation of WAT in absence of an effect on its mass was also observed with other anti-inflammatory interventions for NAFLD/NASH such as an inhibitor of caspase-1 [28] or inhibitor of Ccr2.[45]. Here, CCR2 is linked to metabolic dysfunction-associated steatotic liver disease.